会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • GLYT1 RECEPTOR ANTAGONISTS
    • GLYT1受体拮抗剂
    • WO2010020548A1
    • 2010-02-25
    • PCT/EP2009/060316
    • 2009-08-10
    • F. HOFFMANN-LA ROCHE AGKOLCZEWSKI, SabineNARQUIZIAN, RobertPINARD, Emmanuel
    • KOLCZEWSKI, SabineNARQUIZIAN, RobertPINARD, Emmanuel
    • C07D405/04A61P25/18A61P25/28A61K31/40A61K31/4025C07D305/08C07D231/14C07D241/42C07D319/18C07D333/54C07D498/08C07D295/13C07D491/107
    • C07D305/08C07D231/14C07D241/42C07D295/033C07D319/18C07D333/54C07D491/107C07D498/16
    • The present invention relates to a compound of the general formula (I) wherein R 1 /R 2 are independently from each other lower alkyl, or form together with the N-atom to which they are attached a heterocyclic group, selected from pyrrolidine, piperidine, piperazine, 4-methyl-piperazine, 4-cyclopropyl-piperazine, thiomorpholine, morpholine, 1-(3-oxa-8-aza- bicyclo[3.2.1]oct-8-yl or 1-(2-oxa-6-aza-spiro[3.3]hept-6-yl; X is a bond, -CH 2 - or -O-; Ar 1 is aryl or heteroaryl, which are unsubstituted or substituted by one or two substituents selected from halogen, lower alkyl, lower alkoxy, or lower alkyl substituted by halogen; Ar 2 is aryl or heteroaryl, which are unsubstituted or substituted by one, two or three substituents selected from halogen, lower alkyl, lower alkoxy, hydroxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, benzyl or phenyl; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to their corresponding enantiomers and/or optical isomers thereof. It has surprisingly been found that the compounds of general formula (I) are good inhibitors of the glycine transporter 1 (GIyT-1), and that they have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors.
    • 本发明涉及通式(I)的化合物,其中R 1 / R 2彼此独立地为低级烷基,或与它们所连接的N-原子一起形成杂环基,其选自吡咯烷,哌啶,哌嗪 ,4-甲基 - 哌嗪,4-环丙基 - 哌嗪,硫代吗啉,吗啉,1-(3-氧杂-8-氮杂 - 双环[3.2.1]辛-8-基或1-(2-氧杂-6-氮杂 - 螺[3.3]庚-6-基; X是键,-CH 2 - 或-O-; Ar 1是未取代的或被一个或两个选自卤素,低级烷基,低级烷氧基, 或被卤素取代的低级烷基; Ar 2是未取代的或被1,2或3个选自卤素,低级烷基,低级烷氧基,羟基,被卤素取代的低级烷基,被卤素取代的低级烷氧基,S 或低级烷基,苄基或苯基;或药学上可接受的酸加成盐,与外消旋混合物或其相应的能力 其分子量和/或光学异构体。 惊奇地发现通式(I)的化合物是甘氨酸转运蛋白1(GlyT-1)的良好抑制剂,并且它们对甘氨酸转运蛋白2(GlyT-2)抑制剂具有良好的选择性。
    • 4. 发明申请
    • AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS
    • 作为GLYT-1抑制剂的α-亚氨基 - 和异丁烯酰胺取代的哌啶
    • WO2010086251A1
    • 2010-08-05
    • PCT/EP2010/050551
    • 2010-01-19
    • F. HOFFMANN-LA ROCHE AGKOLCZEWSKI, SabinePINARD, EmmanuelSTALDER, Henri
    • KOLCZEWSKI, SabinePINARD, EmmanuelSTALDER, Henri
    • C07D211/56C07D401/04C07D401/12C07D405/04C07D417/10A61K31/445A61K31/4525A61K31/4535A61K31/4545
    • C07D407/04A61K31/451C07D211/56C07D213/56C07D221/20C07D401/04C07D401/12C07D405/04C07D417/10
    • The present invention relates to a compound of general formula (I) wherein R 1 is hydrogen, lower alkyl, CD 3 , -(CH 2 ) n -CHO, -(CH 2 ) n -O-lower alkyl, -(CH 2 ) n -OH, -(CH 2 ) n -cycloalkyl or is heterocycloalkyl; R 2 is hydrogen, halogen, hydroxy, lower alkyl, di-lower alkyl, -OCH 2 -O-lower alkyl, or lower alkoxy; or the piperidin ring form together with R 2 a spiro ring, selected from 4-aza-spiro[2.5]oct-6-yl; Ar is aryl or heteroaryl, which are optionally substituted by one, two or three substituents, selected from halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cycloalkyl, lower alkoxy, S-lower alkyl, heteroaryl, heterocycloalkyl, or by phenyl optionally substituted by R', and R' is halogen, lower alkyl, lower alkoxy or lower alkoxy substituted by halogen, or is heteroaryl; R is lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein aryl and heteroaryl are optionally substituted by one or two R'; n is 0, 1 2 or 3; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. Furthermore, the present invention relates to pharmaceutical compositions containing the compounds of formula I and to their use in the treatment of neurological and neuropsychiatric disorders.
    • 本发明涉及通式(I)的化合物,其中R1是氢,低级烷基,CD3, - (CH2)n-CHO, - (CH2)nO-低级烷基, - (CH2)n-OH, - ( CH2)n-环烷基或杂环烷基; R2是氢,卤素,羟基,低级烷基,二低级烷基,-OCH2-O-低级烷基或低级烷氧基; 或哌啶环与R2一起形成选自4-氮杂 - 螺[2.5]辛-6-基的螺环; Ar是芳基或杂芳基,其任选被一个,两个或三个选自卤素,低级烷基,被卤素取代的低级烷基,被卤素取代的低级烷氧基,环烷基,低级烷氧基,S-低级烷基,杂芳基,杂环烷基 ,或被R'任意取代的苯基,R'是卤素,低级烷基,低级烷氧基或被卤素取代的低级烷氧基,或是杂芳基; R是低级烷基,环烷基,杂环烷基,芳基或杂芳基,其中芳基和杂芳基任选被一个或两个R'取代; n为0,1 2或3; 或其药学上可接受的酸加成盐,或其相应的对映异构体和/或其旋光异构体。 此外,本发明涉及含有式I化合物的药物组合物及其在治疗神经和神经精神障碍中的用途。